Objective.To evaluate the efficacy and safety of kushenin (KS) combined with nucleoside analogues (NAs) for chronic hepatitis B (CHB).Methods.Randomized controlled trails (RCTs) of KS combined with NAs for CHB were identified through 7 databases.Frequencies of loss of serum HBeAg, HBeAg seroconversion, undetectable serum HBV-DNA, ALT normalization and adverse events at 48 weeks were abstracted by two reviewers.The Cochrane software was performed to assess the risk of bias in the included trials.Data were analyzed with Review Manager 5.3 software.Results.18 RCTs involving 1684 subjects with CHB were included in the analysis.KS combined with NAs including lamivudine (LAM), entecavir (ETV), adefovir dipivoxil (ADV), telbivudine (TLV) showed different degree of improvement in CHB indices.KS combined with NAs increased the frequency of loss of serum HBeAg, HBeAg seroconversion, undetectable HBV-DNA levels and ALT normalization compared with single agents.It also decreased serum ALT and AST level after one-year treatment.Although KS combined with TLV did not show a significant difference in CHB indices.The side-effects of KS combined with NAs were light and low frequency.Conclusion.KS combined with NAs improves the efficacy of NAs in CHB.
Kushenin nucleoside analogues chronic hepatitis B meta-analysis efficacy
Zhe Chen Xiao Ma Yanling Zhao Jiabo Wang Yaming Zhang Yun Zhu Lifu Wang Chang Chen Shizhang Wei Zhirui Yang Man Gong Honghui Shen Zhaofang Bai Yuming Gno Ming Niu Xiaohe Xiao
China Military Institute of Chinese Medicine,302 Hospital of People”s Liberation Army,Beijing,100039 China Military Institute of Chinese Medicine,302 Hospital of People”s Liberation Army,Beijing,100039 Department of Integrative Medical Center,302 Hospital of People”s Liberation Army,Beijing,100039,Chi Pharmacy College,Chengdu University of Traditional Chinese Medicine,Chengdu,611137,China